Analyzing the Global Diabetes Market
Analyzing the Global Diabetes Market
Show Full Description
Diabetes is a chronic disease in which there are high levels of sugar in the blood. The World Diabetes Foundation estimates that there will be 438 million people with diabetes by the year 2030. The global market for products in the management of diabetes currently stands at $41 billion and is on pace to grow to over $114 billion by 2018. Oral anti-diabetics were the leading category of drugs in 2010 and showed a growth rate of 6.3% from the total global sales. The total sales for insulin products increased significantly as well.
Anti-diabetic products include glucose meters, lancets, test strips, continuous blood glucose meters, insulin, insulin pumps, syringes and other insulin delivery devices and anti-diabetic drugs. The bulk of product revenues come from three segments - test strips, insulin and anti-diabetic drugs - which will remain the largest sources of product revenues over the next ten years. The most significant growth, however, will come from the nascent segment of continuous blood glucose monitors, which provide significantly added clinical benefit at only a modestly higher cost compared to standard blood glucose meters.
Top players in the global diabetes market are Novo Nordisk, Eli Lilly, Merck & Co., amongst others. Currently, the US remains the single largest source of product revenues in diabetes management, at roughly 37% of the global market, but that percentage is expected to drop to 28% by 2018, primarily as a result of significant growth in the Asia-Pacific region.
Significant R&D has been observed in the pre-insulin market leading to the development of several novel and safer therapies. The comparative performance of these therapies, such as the DPP-IV inhibitors and GLP-1 analogs is expected to shape the diabetes market landscape through 2015 and in the long term.
Aruvians Rsearch analyzes the Global Diabetes Market in its research offering Analyzing the Global Diabetes Market. The report is a comprehensive analysis of the global diabetes industry.
The report begins with an introduction to diabetes. We analyze the basics of diabetes such as the different types of diabetes including Type 1 diabetes, Type 2 diabetes, gestational diabetes, and others. Complications with diabetes, how the disease is diagnosed, how the extent of diabetes is estimated, diabetes pathophysiology, and the treatment for diabetes are analyzed in this section. We also look at diabetes epidemiology.
Moving to the next section, we analyze the global diabetes market through a market overview and an analysis of the market by diabetes drug classes. We take the drug classes to be insulin, insulin secretagogues, insulin sensitizers, and incretin mimetics. We also analyze the industry through an industry segmentation and an analysis of the leading industry products such as Lantus, Actos, Januvia, Novorapid, and others. We look at the sales figures of the leading 20 products in the industry.
An analysis of the global diabetes industry is not complete without an analysis of the market for insulin. We analyze the market for insulin through an industry overview, and an analysis of the market for human insulin. Within the market for human insulin we analyze the following market segments: fast-acting human insulin analogs, intermediate-acting human insulin analogs, long-acting human insulin analogs, and intermediate and fast-acting human insulin analogs.
With the rapid advances in technology, it is no wonder that there are now many novel emerging drug classes available for the treatment of diabetes. Some of these novel emerging drug classes for diabetes treatment are analyzed in our report. We analyze alpha-glucosidase inhibitors such as Basen, biguanides such as glucophages, DPP-IV inhibitors such as Januvia, glitazones such as Actos, GLP-1 agonists such as Victoza and Byetta, sulfonylureas such as Amaryl, amongst others.
Moving on, we carry out an analysis of some of the key molecules used in the treatment of diabetes today. Some of the molecules analyzed include Degludec, Victoza, Syncria, amongst others.
An analysis of the diabetes market in India and China, two of the countries with the largest prevalence of diabetes, is also included, along with a look at industry research and development.
Competition in the industry is analyzed in the report, following which we move on to the analysis of the major players in the global diabetes industry. Players in the industry are analyzed through a corporate profile, an analysis of their major business segments, their major products and services offered, a financial analysis, and an analysis of their presence in the diabetes market. We also look at their diabetes R&D pipeline, along with the company strategy for future growth in the diabetes industry. A SWOT analysis of the players completes the analysis of the major industry contributors.
Future perspective of the global diabetes market completes this in-depth profile of the global diabetes market from Aruvians Rsearch.
Show Table of Contents